We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Maz5.0
Mazdutide Research
Too few graded studies
27 peer-reviewed studies
What the evidence says
Too few graded studies
Mazdutide doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2021–2026 with a typical study size of 461 participants.
Based on 27 studies · 6 meta-analyses · 11 RCTs · 1,252 total participants
Confidence
High confidence
By outcome
Weight managementPhase-3 trials showed ~11-14% weight loss at 48 weeks and ~16.7% at 60 weeks (9 mg) versus placebo in Chinese adults · Months (dose-escalated)
Too few graded studies23 studies
Glycemic & metabolic controlLowered HbA1c by up to ~2.2% vs placebo (phase-3 monotherapy); superior to dulaglutide head-to-head · Weeks to months
Too few graded studies16 studies
Safety profile
Too few graded studies6 studies
Heart & blood pressure
Too few graded studies2 studies
Liver fat & MASLD
Too few graded studies1 study
Active research area
27 studies in the last 5 years · Latest meta-analysis: 2026
20212026
1Meta-Analysis2026
In plain English: Obesity drugs produce variable weight loss at one year, with larger benefits generally accompanied by greater harms and discontinuation.
Nong K, Shi Q, Xie X, Wang Y, Agarwal A, Guyatt GH, Zhang H, Gao Y, Khunti K, Le Roux CW, Widyahening IS, Fan Q, Liu T, Mao Y, Florez ID, Du H, Pan X, Zou X, Wang C, Sun X, Li J, Hao Q, Jia Q, Sun F, Zhu Z, Agoritsas T, Tian H, Vandvik PO, Li S. · BMJ (Clinical research ed.) (2026)
Emerging agents (ecnoglutide, mazdutide, retatrutide) may produce similar or greater reductions (13.1-14.6%; very low to low certainty).
Tirzepatide reduced fat mass the most (by 25.7%) but also lean mass the most (by 8.3%).
Subcutaneous semaglutide was the only drug associated with reduced all cause mortality (risk ratio 0.81, 95% confidence interval 0.72 to 0.93) and myocardial infarction (0.72, 0.61 to 0.85), with these estimates largely informed by cardiovascular outcome trials in high risk populations.
In plain English: Multi-receptor drugs demonstrated substantial therapeutic potential in weight management, glycemic control, and blood pressure regulation in adults with overweight or obesity, with or without diabetes, with a generally favorable safety profile.
Liu S, Hu J, Zhao C, Liu H, He C. · Frontiers in endocrinology (2025)
In patients with type 2 diabetes, all agents reduced HbA 1c by over 1%, with Tirzepatide (MD: -1.87%, 95% CI: -2.15 to -1.59, P-score: 0.87, p < 0.0001) and Mazdutide (MD: -1.89%, 95% CI: -2.43 to -1.35, P-score: 0.88, p < 0.0001) showing the greatest effects on glycemic control.
Non-diabetic participants showed more pronounced improvements in both weight and blood pressure.
Safety analysis revealed that Tirzepatide had a favorable safety profile and all agents showed no significant impact on serious adverse events compared to placebo.
In plain English: At week 60, the mean percentage change in body weight from baseline was -16.65%... in the mazdutide group compared with -1.50%... in the placebo group.
Gao L, Jiang H, Cai H, Tian J, Shi B, Qiu W, Huang C, et al. · JAMA (2026)
60-week phase-3 double-blind placebo-controlled RCT (GLORY-2) in 461 Chinese adults with obesity (BMI >=30), mazdutide 9 mg vs placebo
Mean weight change -16.65% vs -1.50% placebo (between-group difference -15.15%); 84.3% lost >=5% vs 33.1%
GI adverse events common at 9 mg: vomiting 53.1%, nausea 46.9%, diarrhea 39.4% (most mild-to-moderate)
In plain English: Once-weekly, subcutaneous mazdutide showed clinically meaningful bodyweight reduction in adults with obesity or overweight across all studied doses, with higher doses (10 mg and 16 mg) showing additional weight reduction.
Hsia SH et al. · The lancet. Diabetes & endocrinology (2026)
Once-weekly, subcutaneous mazdutide showed clinically meaningful bodyweight reduction in adults with obesity or overweight across all studied doses, with higher doses (10 mg and 16 mg) showing additional weight reduction.
In plain English: The information provided herein furthers the understanding of obesity management, implying direct clinical implications and stimulating research initiatives.
Kokkorakis M, Chakhtoura M, Rhayem C, Al Rifai J, Ghezzawi M, Valenzuela-Vallejo L, Mantzoros CS. · Pharmacological reviews (2025)
Completed phase 2 trials on incretin-based therapies showed a mean percent weight loss of 7.4% to 24.2%.
Except for the newer injectable medications, drugs with suboptimal efficacy have been available in the clinician's armamentarium for weight management.
However, emerging alternatives of novel agents and combinations populate the current obesity therapeutic pipeline.
In plain English: We call for people-centred, integrated systems that embed whole-person obesity care within a planetary health framework and deliver a coherent continuum of prevention, treatment, and long-term support.
Pan XF, Fang ZZ, Zhang L, Pan A. · The lancet. Diabetes & endocrinology (2026)
Since 2021, five additional GLP-1 receptor agonists (including liraglutide, beinaglutide, semaglutide, tirzepatide, and mazdutide) have been approved in China for weight management, broadening therapeutic choices and initiating a transformation in obesity care.
Nevertheless, several key challenges remain which can undermine the sustained impact of the progress.
We call for people-centred, integrated systems that embed whole-person obesity care within a planetary health framework and deliver a coherent continuum of prevention, treatment, and long-term support.
In plain English: Mazdutide was associated with dose-dependent reductions in body weight and HbA1c, with broader metabolic benefits in predominantly Chinese adults with obesity and/or T2D.
Kamrul-Hasan ABM, Chatterjee S, Ashraf H, Nagendra L, Khalil I, Hasan M, Ahsan A, Dutta D. · Diabetes, obesity & metabolism (2026)
Co-primary outcomes were percent change in body weight and change in HbA1c.
Random-effects models were used to generate pooled mean differences (MDs) or risk ratios with 95% confidence intervals, and the certainty of the evidence (COE) was assessed using GRADE.
In overweight/obesity without diabetes, mazdutide 3, 4, and 6 mg reduced body weight more than placebo (MDs -6.56%, -9.92%, and -11.1%, respectively; very low COE due to substantial heterogeneity and few trials).
In plain English: Both doses of mazdutide showed non-inferiority and superiority to the 1.5-mg dose of dulaglutide in terms of the mean change in... HbA1c... and significantly greater reductions in body weight.
Guo L, Zhang B, Xue X, Zhang X, Cai H, Jiang H, Zhang L, et al. · Nature (2026)
Phase-3 head-to-head RCT in 731 Chinese adults with type 2 diabetes on background oral agents, mazdutide 4/6 mg vs dulaglutide 1.5 mg for 28 weeks
HbA1c treatment difference vs dulaglutide -0.24% (4 mg) and -0.30% (6 mg) — non-inferior and superior
Greater weight loss vs dulaglutide: difference -3.78% (4 mg) and -5.76% (6 mg)
In plain English: These results suggest that mazdutide and cotadutide are effective for glycaemic control and weight reduction in individuals with T2DM, obesity, or both.
Deng B, Ruan T, Lu W, Ying J, Li S, Zhou R, Mu D. · Endocrine (2024)
The primary outcomes assessed were changes in HbA1c level and percentage changes in body weight from baseline (CFB).
The pooled meta-analysis revealed a significant reduction in HbA1c (MD = -0.63%; 95% CI = [-0.82, -0.44]; P < 0.00001), fasting plasma glucose (MD = -1.71 mmol/L; 95% CI = [-2.31, -1.10]; P < 0.00001), and percentage change in body weight (MD = -4.16%; 95% CI = [-5.41, -2.92]; P < 0.00001).
Results Eleven studies and four unpublished trials were included.
In plain English: Cardiovascular effects of GCGR signaling by dual agonists should be clarified per compound by ongoing clinical trials, notably the cardiovascular outcomes trial SYNCHRONIZE-CVOT (A Study to Test the Effect of Survodutide [BI 456906] on Cardiovascular Safety in People With Overweight or Obesity) and thorough corrected QT study of survodutide.
Kushner PR, Michos ED. · Journal of the American Heart Association (2026)
Mazdutide and survodutide also reduced blood pressure and hyperglycemia.
However, at least 1 other dual agonist was discontinued, partly due to unacceptably large increases in heart rate and prolongation of the corrected QT interval.
These between-compound differences may reflect different potencies for activating the GCGR and GLP-1 receptors.
In plain English: By summarizing mechanistic insights, clinical progress, and translational prospects, this review aims to inform the development of individualized and integrative therapeutic strategies for hyperuricemia.
Li X, Chen Z, Zhang Y, Fan C, Chen L, Xu X, Chang J, Qiang W, Jiang H, Liu C. · Frontiers in endocrinology (2025)
It focuses on elaborating the research breakthroughs of URAT1 inhibitor derivatives and the new drug SHR4640.
At the same time, it details the action pathways and clinical evidence of emerging therapies such as SGLT2 inhibitors, the GLP-1/GCG dual-receptor agonist Mazdutide, probiotics, and washed microbiota transplantation (WMT).
By summarizing mechanistic insights, clinical progress, and translational prospects, this review aims to inform the development of individualized and integrative therapeutic strategies for hyperuricemia.